Zentalis Pharmaceuticals (ZNTL) Expected to Announce Quarterly Earnings on Tuesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect Zentalis Pharmaceuticals to post earnings of ($0.70) per share for the quarter.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million for the quarter. On average, analysts expect Zentalis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock remained flat at $1.45 during mid-day trading on Friday. The stock had a trading volume of 700,222 shares, compared to its average volume of 1,550,091. The firm has a market capitalization of $104.13 million, a PE ratio of -0.58 and a beta of 1.80. Zentalis Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $13.24. The company has a 50-day moving average of $1.57 and a 200-day moving average of $2.45.

Analyst Ratings Changes

ZNTL has been the topic of a number of recent analyst reports. Wedbush reaffirmed a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th. Wells Fargo & Company lowered their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th. UBS Group dropped their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $8.24.

Insider Transactions at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers bought 21,000 shares of the stock in a transaction that occurred on Wednesday, April 30th. The shares were bought at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the purchase, the director now owns 281,192 shares in the company, valued at $393,668.80. This represents a 8.07 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Ingmar Bruns purchased 20,000 shares of the business's stock in a transaction on Thursday, February 6th. The stock was acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now directly owns 36,629 shares in the company, valued at $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company's stock.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.